Clinical monitoring of hirudin and direct thrombin inhibitors.

  title={Clinical monitoring of hirudin and direct thrombin inhibitors.},
  author={Goetz Nowak},
  journal={Seminars in thrombosis and hemostasis},
  volume={27 5},
  • Goetz Nowak
  • Published 2001 in Seminars in thrombosis and hemostasis
In addition to heparin, the standard medication for prophylaxis and therapy of thromboembolism, several other substances have been developed and tested for clinical use with the aim of decreasing or eliminating side effects. Most of all, hirudin, a direct antithrombin (AT), has proved to be effective. To define the therapeutic range and to avoid underdosage or overdosage, clinical monitoring is necessary. For monitoring of hirudin, thrombin time (TT) is not suited because of the missing… CONTINUE READING